AbbVie (ABBV) Stock Overview
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Last Earnings Call
Q2 2026 · 31 Jul 2026AbbVie (NYSE: ABBV) reported a strong second quarter for 2026, with net revenues of approximately $17 billion, a 10.2% increase year-over-year 1. Adjusted EPS reached $3.65, surpassing the guidance midpoint 1. Growth was driven by Skyrizi (+24%) and Rinvoq (+23.7%), alongside a robust neuroscience portfolio (+20%) 1. Humira sales declined 36.1% as expected 1.
Management raised full-year revenue guidance by $300 million 1. However, adjusted EPS guidance for the full year was set at $13.87–$14.07, factoring in $0.14 dilution from the pending Apogee Therapeutics acquisition 1.
Analyst Consensus vs. Reported Results:
- Revenue: Analyst consensus was approximately $16.7 billion. AbbVie beat this estimate by $300 million 1.
- EPS: Analyst consensus was $3.59. AbbVie beat this estimate by $0.06 1.
Market Reaction
AbbVie's stock rose by approximately 3.2% on July 31, 2026. Analysts attributed the positive reaction primarily to the company’s strong "double-digit" growth in key immunology assets, upward revenue guidance revisions, and optimism surrounding the pipeline, specifically the upcoming subcutaneous Skyrizi launch and the acquisition of Apogee Therapeutics.
ABBV Community Fair Values
Create NarrativeSee what 489 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AbbVie Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$246.04 |
| 52 Week High | US$267.47 |
| 52 Week Low | US$190.75 |
| Beta | 0.28 |
| 1 Month Change | -0.82% |
| 3 Month Change | 21.33% |
| 1 Year Change | 24.23% |
| 3 Year Change | 61.68% |
| 5 Year Change | 111.23% |
| Change since IPO | 602.97% |
Recent News & Updates
ABBV: Future Returns Will Hinge On Apogee Respiratory Bet
Analysts have nudged their fair value estimate for AbbVie higher to about $273 per share. This reflects refreshed models that factor in Q2 updates, stronger confidence in long term margins, and the potential impact of the Apogee acquisition, while still using a slightly higher discount rate and a modestly lower future P/E assumption.AbbVie: Strong Q2 And New Catalysts Keep Me Bullish
Summary On June 29, AbbVie Inc. stock reached a 52-week high of $267.47. But over the past five days, its shares have fallen 6.2% despite strong Q2 earnings. Rinvoq sales grew 24.5% YoY and 19.2% quarter-over-quarter to about $2.53 billion in Q2. Meanwhile, Elahere, used to treat certain patients with ovarian cancer, generated $211 million in revenue for AbbVie in Q2, up 32.7% year-over-year. In this article, you'll learn why AbbVie, my favorite in immunology, still offers an attractive risk/reward profile. Read the full article on Seeking AlphaRecent updates
ABBV: Future Returns Will Hinge On Apogee Respiratory Bet
Analysts have nudged their fair value estimate for AbbVie higher to about $273 per share. This reflects refreshed models that factor in Q2 updates, stronger confidence in long term margins, and the potential impact of the Apogee acquisition, while still using a slightly higher discount rate and a modestly lower future P/E assumption.AbbVie: Strong Q2 And New Catalysts Keep Me Bullish
Summary On June 29, AbbVie Inc. stock reached a 52-week high of $267.47. But over the past five days, its shares have fallen 6.2% despite strong Q2 earnings. Rinvoq sales grew 24.5% YoY and 19.2% quarter-over-quarter to about $2.53 billion in Q2. Meanwhile, Elahere, used to treat certain patients with ovarian cancer, generated $211 million in revenue for AbbVie in Q2, up 32.7% year-over-year. In this article, you'll learn why AbbVie, my favorite in immunology, still offers an attractive risk/reward profile. Read the full article on Seeking AlphaABBV: Future Returns Will Rely On Apogee Deal And Broader Pipeline Execution
AbbVie’s updated analyst price target has increased to $266.89 from $259.46 as analysts factor in recent Q2 preview research, higher modeled profit margins, and a slightly adjusted discount rate and future P/E outlook. Analyst Commentary Recent research commentary around AbbVie points to a broadly constructive tone ahead of Q2 results, with several firms revisiting their models, adjusting P/E assumptions, and updating margin and pipeline expectations.ABBV: Future Returns Will Depend On Apogee Deal And Broader Immunology Expansion
AbbVie’s refreshed analyst price target framework edges higher to about $259 from roughly $254, with analysts pointing to updated Q2 models, recent target hikes across several firms, and added confidence around the Apogee acquisition’s immunology and respiratory potential as key supports for the revision. Analyst Commentary Recent research on AbbVie centers on two main themes, the refreshed Q2 earnings models and the planned Apogee Therapeutics acquisition.ABBV: Future Returns Will Hinge On Apogee Deal And Immunology Pipeline
Analysts have made only a modest adjustment to AbbVie’s fair value narrative, reflecting a slightly higher discount rate and updated views on margins and long term P/E in light of the proposed $10.9 billion Apogee Therapeutics deal and its implications for competition and atopic dermatitis market potential. Analyst Commentary Recent research on AbbVie around the proposed US$10.9b Apogee Therapeutics acquisition highlights a mix of optimism about growth opportunities in immunology and atopic dermatitis, alongside caution about execution risk, competition, and valuation.AbbVie (ABBV) Stock Could Be 12.6% Undervalued After CLL14 Trial Update
AbbVie (ABBV) is back in focus after releasing nine year final results from its Phase 3 CLL14 trial, where a fixed duration venetoclax plus obinutuzumab regimen improved progression free survival in untreated CLL patients. See our latest analysis for AbbVie. The latest CLL14 update lands after a mixed few sessions for AbbVie, with the share price slipping 2.7% on the day to $221.59, while still showing a 5.3% 30 day share price return and a 19.9% one year total shareholder return that points...ABBV: Future Returns Will Depend On Expanding Immunology And IBD Pipeline Execution
AbbVie’s updated analyst price target edges higher to $253.55 from $249.43 as analysts factor in slightly higher profit margin assumptions, modestly lower revenue growth expectations, a reduced discount rate, and a somewhat lower future P/E multiple, with recent research highlighting the depth of the inflammatory bowel disease pipeline and broader R&D optionality. Analyst Commentary Recent Street research on AbbVie shows a mix of optimism and caution, with multiple price target revisions clustered within a relatively tight range and commentary that keeps attention on the inflammatory bowel disease pipeline and broader R&D portfolio.We Think You Can Look Beyond AbbVie's (NYSE:ABBV) Lackluster Earnings
The market was pleased with the recent earnings report from AbbVie Inc. ( NYSE:ABBV ), despite the profit numbers being...ABBV: Future Returns Will Rely On Immunology Expansion And Operating Leverage Execution
Analysts made a small upward adjustment to AbbVie’s fair value estimate to about $249. The modest change reflects a mix of slightly higher assumed discount rates and future P/E multiples, alongside recent shifts in Street price targets, including both raises and trims from firms such as Piper Sandler, Guggenheim, Cantor Fitzgerald, Evercore ISI, Citi and UBS, as well as fresh bullish initiations from Canaccord, RBC Capital and Barclays.ABBV: Future Returns Will Hinge On Immunology Encore And Operating Leverage Execution
Analysts have made a modest upward adjustment to AbbVie’s price target, reflecting updated views on its immunology pipeline potential, operating leverage, and the ongoing debate about whether recent share underperformance and selloffs adequately reflect competitive risks. Analyst Commentary Recent research on AbbVie highlights a split view, with some analysts focusing on the upside from the immunology pipeline and operating leverage, while others point to valuation and competitive questions after a period of share underperformance.ABBV: Future Returns Will Hinge On Immunology Encore Outweighing Competitive Concerns
Narrative Update The analyst price target for AbbVie has been adjusted slightly higher to reflect a fair value move to about $249. Analysts point to early stage indication expansion, operating leverage potential, and ongoing immunology pipeline developments, even as some firms flag emerging competition and a more balanced risk and reward profile.ABBV: Future Returns Will Depend On Immunology Encore And Deal Optionality Uncertainty
The analyst price target for AbbVie edges higher to align with our fair value shift from $248.29 to $248.86, as analysts highlight ongoing indication expansion in immunology, potential operating leverage, and multiple expansion drivers, even as some firms note emerging competition and a more balanced risk and reward profile. Analyst Commentary Recent research on AbbVie reflects a split view, with some analysts pointing to upside tied to immunology growth and pipeline execution, while others flag competition risk and a more balanced risk and reward profile at current levels.ABBV: Future Returns Will Rely On Immunology Encore And Evolving Deal Optionality
Our updated AbbVie narrative reflects a modest price target increase to about $248 per share, as analysts point to potential operating leverage, room for P/E multiple expansion, and a pipeline of proof-of-concept and immunology programs that could support slightly higher revenue growth assumptions, even as margin expectations are trimmed. Analyst Commentary Recent research shows a mix of optimism and caution around AbbVie, with several firms adjusting price targets and ratings as they reassess execution risks, competitive pressures, and the potential impact of the pipeline on valuation.ABBV: Future Returns Will Depend On Immunology Pipeline Clarity And M&A Uncertainty
Analysts have trimmed their price targets for AbbVie by a small amount. This reflects slightly lower revenue growth and P/E assumptions, while also incorporating a modestly higher profit margin and recent mixed research views around competition and pipeline visibility.ABBV: Future Returns Will Hinge On Post-Humira Immunology And Deal Optionality
Analysts have nudged their price target for AbbVie slightly higher to reflect a fair value estimate of about $245 per share, supported by updated assumptions for revenue growth, profit margins, and a modestly lower future P/E. Recent research highlights both increased price targets and more cautious views around competition and the sustainability of outperformance in key immunology drugs.ABBV: Future Returns Will Depend On Post-Humira Immunology And Pipeline Execution
Analysts have trimmed their AbbVie fair value estimate by about $0.10 per share to roughly $244.56. This reflects a mix of slightly higher risk assumptions, modestly adjusted revenue and margin expectations, and a more balanced set of views after recent downgrades and price target changes that suggest outperformance is already well reflected in the current share price.AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 17th of February to...ABBV: Future Returns Will Hinge On Post-Humira Immunology And Pipeline Execution
Analysts have nudged our AbbVie fair value estimate slightly higher, from $243.55 to $244.68. This reflects modestly stronger long term revenue growth expectations for key immunology franchises and pipeline assets, partially offset by slightly lower margin assumptions and a broadly constructive but mixed backdrop of recent price target revisions and rating changes across the Street.ABBV: Future Performance Will Depend On Extended Exclusivity And Pipeline Execution
Analysts have nudged their average price target on AbbVie modestly higher to reflect a wave of target increases into the mid 240s to low 260s dollar range, supported by stronger visibility into Skyrizi and Rinvoq driven growth, extended Rinvoq exclusivity, and a more favorable large cap biopharma backdrop despite mixed ratings changes. Analyst Commentary Recent research paints a generally constructive picture on AbbVie, with most price target revisions skewing higher even as some firms move to the sidelines.AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73
The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...ABBV: Future Performance Will Depend On Pipeline Expansion And Patent Protections
AbbVie’s analyst price target has increased modestly from $241.29 to $243.55. Analysts cite resilient performance in immunology products, extended Rinvoq exclusivity, and improving fundamentals as key drivers of sentiment.AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...Shareholder Returns
| ABBV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.0% | 6.3% | 4.2% |
| 1Y | 24.2% | 40.9% | 20.6% |
Return vs Industry: ABBV underperformed the US Biotechs industry which returned 40.9% over the past year.
Return vs Market: ABBV exceeded the US Market which returned 20.6% over the past year.
Price Volatility
| ABBV volatility | |
|---|---|
| ABBV Average Weekly Movement | 4.1% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ABBV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ABBV's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 57,000 | Robert Michael | www.abbvie.com |
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions.
AbbVie Inc. Fundamentals Summary
| ABBV fundamental statistics | |
|---|---|
| Market cap | US$434.78b |
| Earnings (TTM) | US$6.27b |
| Revenue (TTM) | US$64.39b |
Is ABBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABBV income statement (TTM) | |
|---|---|
| Revenue | US$64.39b |
| Cost of Revenue | US$17.52b |
| Gross Profit | US$46.87b |
| Other Expenses | US$40.60b |
| Earnings | US$6.27b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.55 |
| Gross Margin | 72.79% |
| Net Profit Margin | 9.74% |
| Debt/Equity Ratio | -1,203.9% |
How did ABBV perform over the long term?
See historical performance and comparisonDividends
Does ABBV pay a reliable dividends?
See ABBV dividend history and benchmarks| AbbVie dividend dates | |
|---|---|
| Ex Dividend Date | Jul 15 2026 |
| Dividend Pay Date | Aug 14 2026 |
| Days until Ex dividend | 26 days |
| Days until Dividend pay date | 4 days |
Does ABBV pay a reliable dividends?
See ABBV dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/09 12:11 |
| End of Day Share Price | 2026/08/07 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AbbVie Inc. is covered by 51 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Luisa Hector | Berenberg |